Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON34970
NL-OMON34970WithdrawnNot Applicable

Platelet reactivity in diabetic patients and the effects of different antithrombotic agents on the results of multiple platelet function tests - PREDATOR

Internal Medicine0 sites600 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Sponsor
Enrollment
600
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •-Male and female patients with a diagnosis of Type 2 Diabetes Mellitus according to the WHO-criteria
  • •->40 years
  • •-willing to provide informed consent;Controls
  • •->40 years
  • •-willing to provide informed consent

Exclusion Criteria

  • •- a history of coronary heart disease (either stable angina with angiographic confirmed significant coronary artery disease or an acute coronary syndrome)
  • •- a history of cerebrovascular disease consisting of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack
  • •- a history of arteriosclerotic disease necessitating medical treatment
  • •- <=40 years or >75 years
  • •- weight <60kg
  • •- no Diabetes Mellitus
  • •- atrial fibrillation
  • •- Women who are known to be pregnant or who have given birth within the past 90 days, or who are breastfeeding.
  • •- use of antiplatelet or antithrombotic therapy within the last 10 days (aspirin, NSAIDS, clopidogrel, prasugrel, ticlopidine, dipyridamole, acenocoumarol, fenprocoumon, argatroban, LMW) heparin
  • •- a history of severe gastric or duodenal ulcer
  • •- severe liver dysfunction
  • •- use of steroid-treatment within the last 30 days
  • •- severe renal dysfunction
  • •- Allergy to either aspirin, clopidogrel or prasugrel.
  • •- Patients who are unwilling and/or unable to give informed consent;
  • •- Patients at increased risk of death from a pre-existing concurrent illness;Controls
  • •- a history of coronary heart disease (either stable angina with angiographic confirmed significant coronary artery disease or an acute coronary syndrome)
  • •- a history of cerebrovascular disease consisting of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and transient ischemic attack
  • •- a history of arteriosclerotic disease necessitating medical treatment
  • •- <=40 years or >75 years
  • •- weight <60kg
  • •- Diabetes Mellitus
  • •- atrial fibrillation
  • •- Women who are known to be pregnant or who have given birth within the past 90 days, or who are breastfeeding.
  • •- use of antiplatelet or antithrombotic therapy within the last 10 days (aspirin, NSAIDS, clopidogrel, prasugrel, ticlopidine, dipyridamole, acenocoumarol, fenprocoumon, argatroban
  • •- a history of severe gastric or duodenal ulcer
  • •- severe liver dysfunction
  • •- use of steroid-treatment within the last 30 days
  • •- severe renal dysfunction
  • •- Allergy to either aspirin, clopidogrel or prasugrel.
  • •- Patients who cannot communicate reliably with the investigator;
  • •- Patients who are unwilling and/or unable to give informed consent;
  • •- Patients at increased risk of death from a pre-existing concurrent illness

Investigators

Sponsor
Internal Medicine

Similar Trials

Active, not recruiting
Phase 1
Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatmentDiabetes mellitus type 2, without or with renal impairment
EUCTR2004-004416-22-SEKarolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit60
Completed
Not Applicable
Comparison of Effects of Buffered and Enteric-coated Forms of Aspirin on Platelet Aggregation in Patients With Diabetes Mellitus and Chronic Coronary SyndromeDiabetes Mellitus Type 2Coronary Artery DiseasesAspirin Resistance
NCT06716255Nizhpharm200
Active, not recruiting
Not Applicable
se of platelet eyedrops in diabetic patients with dry eye disease.dry eye diseasediabetesC11.496.260
RBR-96t463Hemocentro de Alagoas-HEMOA
Unknown
Not Applicable
Platelet Activity in T2DM Using FlowcytometryPlatelet Activity in T2DM Using Flowcytometry
NCT04027907Assiut University122
Recruiting
Not Applicable
Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCIIndividualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention
NCT05911659Mina Wageh Mohareb60